v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenues:        
Total revenues     $ 37 $ 1,424
Operating expenses:        
Research and development $ 67,407 $ 62,931 207,950 169,741
General and administrative 14,844 10,686 39,396 31,897
Total operating expenses 82,251 73,617 247,346 201,638
Operating loss (82,251) (73,617) (247,309) (200,214)
Investment and other income, net 6,694 6,573 19,564 22,774
Net loss $ (75,557) $ (67,044) $ (227,745) $ (177,440)
Basic net loss per common share (in dollars per share) $ (0.96) $ (1.01) $ (3.06) $ (2.67)
Diluted net loss per common share (in dollars per share) $ (0.96) $ (1.01) $ (3.06) $ (2.67)
Shares used in calculating basic net loss per share (in shares) 78,531 66,420 74,356 66,399
Shares used in calculating diluted net loss per share (in shares) 78,531 66,420 74,356 66,399
Comprehensive loss:        
Net loss $ (75,557) $ (67,044) $ (227,745) $ (177,440)
Other comprehensive (loss) income:        
Unrealized (loss) gain on marketable securities (1,627) 426 (3,955) 451
Comprehensive loss $ (77,184) $ (66,618) (231,700) (176,989)
Product development and licensing agreements        
Revenues:        
Total revenues     7 57
Contracts and grants        
Revenues:        
Total revenues     $ 30 $ 1,367